2Giannessi D, Del Ry S, Vitale RL.The role of endothelins and their receptors in heart failure. Pharmacol Res,2001,43:111-126.
3Piepho RW. Overview of the angiotensin-converting-enzyme inhibitors. Am J Health Syst Pharm, 2000,57 : S3-7.
4Eryonucu B, Koldas L, Ayan F,et al. Comparison of the first dose response of fosinopril and captopril in congestive heart failure: a randomized, doubleblind, placebo controlled study. Jpn Heart J, 2001,42:185-191.
5Ergul A, Grubbs AL, Zhang Y, et al. Selective upregulation of endothelin converting enzyme-la in the human failing heart. J Card Fail,2000,6:314- 320.
6Ergul A. Endothelin-1 and endothelin receptor antagonists as potential cardio- vascular therapeutic agents. Pharmacotherapy, 2002,22: 54-65. Review.
7Oberhoff M, Novak D, Herdeg C, et al. Local and systemic delivery of low molecular weight heparin stimulates the reendothelialization after balloon angioplasty. Cardiovasc Res, 1998,38 : 751-762.
8Ho KK, Anderson KM, Kannel WB, et al. Survivalafter the onset of congestive heart failure in Framingham Heart Study subjects[J]. Circulation, 1993, 88(1):107- 115.
9Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells[J]. Nature, 1988, 332(6163) :411 - 415.
10Sutsch G, Kiowski W. Endothelin and endothelin receptor antagonist in heart failure [J]. J Cardiovasc Pharmacol,2000, 35(4 Suppl 2):S69- S73.
